

ESMO Virtual Advanced Course on NTRK Gene Fusion: A New Target in Precision Treatment of Cancer

Programme

**ESMO VIRTUAL
ADVANCED COURSE**

6-7 DECEMBER 2021

Co-Chairs

Tsuyoshi Saito, Japan

Silvia Stacchiotti, Italy

Iain Bee Huat Tan, Singapore

ESMO VIRTUAL ADVANCED COURSE PROGRAMME

NTRK GENE FUSION: A NEW TARGET IN PRECISION TREATMENT OF CANCER

6-7 December 2021

CO-CHAIRS: Tsuyoshi Saito, Japan
Silvia Stacchiotti, Italy
Iain Bee Huat Tan, Singapore

SPEAKERS: Cristina Antonescu, United States
Jean-Yves Blay, France
Tom Wei-Wu Chen, Taiwan
Yuhki Koga, Japan
Laura Locati, Italy
Makoto Tahara, Japan
Winette T.A. van der Graaf, Netherlands

LEARNING OBJECTIVES

- Acquire knowledge of the TRK family members and their roles in ontogenesis
- Understand the mechanisms of gene fusion and the different fusion partners involved
- Learn how TRK receptors are structured and how their activation impacts signal transduction
- Review the epidemiology of NTRK gene fusion in human tumors
- Understand the methodology to identify NTRK gene fusion and the challenges of testing
- Update knowledge on the present outcome obtained with NTRK inhibitors, their toxicities and clinical management

ACCREDITATION

The programme of this event has been accredited with **6 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



All timings are to be considered GMT+ 8 (Singapore local time 3:00 pm)

(Local time in Tokyo: 04:00 pm, Switzerland/Italy: 08:00 am)

Monday, 6 December 2021

15:00-15:05 5'	Welcome and introduction Tsuyoshi Saito, JP Silvia Stacchiotti, IT Iain Bee Huat Tan, SG
15:05-15:35 20'	Session 1 Advances in NTRK-fused tumors classification and diagnosis Cristina Antonescu, US
10'	Discussion
15:35-16:00 15'	Session 2 Epidemiology and distribution of NTRK gene fusion in human tumors Iain Bee Huat Tan, SG
10'	Discussion
16:00-16:25 15'	Session 3 Structure and function of TRK and NTRK in ontogenesis and which are the molecular alterations of interest to consider a treatment with NTRK inhibitors Tsuyoshi Saito, JP
10'	Discussion
16:25-16:40	<i>Break</i>
16:40-17:30 20'	Session 4 Clinical data on larotrectinib: activity, efficacy and safety Makoto Tahara, JP
20'	Clinical data on entrectinib: activity, efficacy and safety Winette T.A. van der Graaf, NL
10'	Discussion
17:30-18:30 60'	Session 5 Clinical cases; how to treat NTRK-fused tumors 15' Pediatric NTRK rearranged tumor Yuhki Koga, JP 15' Adult NTRK rearranged sarcoma, preoperative Silvia Stacchiotti, IT 15' Adult head and neck Laura Locati, IT 15' Discussion

Tuesday, 7 December 2021

15:00-15:30 20'	Session 6 NTRK-fused tumors: when to treat and when not to treat with NTRK inhibitors Tom Wei-Wu Chen, TW
10'	Discussion
15:30-16:10 30'	Session 7 Acquired resistance to NTRK inhibitors and development of inhibitors targeting resistance mutations Jean-Yves Blay, FR
10'	Discussion
16:10-16:25	<i>Break</i>
16:25-17:55	Workshop session
Workshop 1 90'	Workshop for Medical Oncologists & Pathologists Cristina Antonescu, US Tom Wei-Wu Chen, TW Tsuyoshi Saito, JP Silvia Stacchiotti, IT Makoto Tahara, JP Iain Bee Huat Tan, SG Structure: <ul style="list-style-type: none">• Presentation of 1/2 clinical cases by speakers (1/2 different NTRK tumours type)• Technical aspects of NTRK diagnosis technics (theoretical aspects, methods)• Discussion & questions
17:55-18:10 15'	Synthesis and wrap-up
18:10-18:25 15'	Conclusion and farewell Tsuyoshi Saito, JP Silvia Stacchiotti, IT Iain Bee Huat Tan, SG